Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care

Arthritis Care Res (Hoboken). 2010 Mar;62(3):293-5. doi: 10.1002/acr.20088.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, N.I.H., Intramural

MeSH terms

  • Antibodies, Monoclonal / economics*
  • Benchmarking
  • Biological Factors / economics*
  • Humans
  • Infliximab
  • Medicare Part B / economics
  • Medicare Part D / economics*
  • Reimbursement, Incentive*
  • United States

Substances

  • Antibodies, Monoclonal
  • Biological Factors
  • Infliximab